Commission Regulation (EU) No 143/2011 [Commission Regulation (EU) No 143/2011 of 17 February 2011 amending Annex XIV to Regulation (EC) No 1907/2006 of the European Parliament and of the Council on the Registration, Evaluation, Authorisation and Restriction of Chemicals (‘REACH’) (OJ L 44, 18.2.2011, p. 2).] exempted from the authorisation requirement the use of DEHP, BBP and DBP in the immediate packaging of medicinal products covered by Regulation (EC) No 726/2004 of the European Parliament and of the Council [Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (OJ L 136, 30.4.2004, p. 1).], Directive 2001/82/EC of the European Parliament and of the Council [Directive 2001/82/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to veterinary medicinal products (OJ L 311, 28.11.2001, p. 1).] and/or Directive 2001/83/EC of the European Parliament and of the Council [Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (OJ L 311, 28.11.2001, p. 67).]. The judgment of the Court of Justice of 13 July 2017 in Case C-651/15 P, VECCO and Others v. Commission [Judgment of the Court of Justice of 13 July 2017, Verein zur Wahrung von Einsatz und Nutzung von Chromtrioxid und anderen Chrom-VI-Verbindungen in der Oberflächentechnik eV (VECCO) and Others v European Commission, C-651/15 P, ECLI:EU:C:2017:543.], provided clarifications on certain aspects of Article 58(2) of Regulation (EC) No 1907/2006 for granting an exemption from the authorisation requirement. The Commission has re-assessed the exemption set out in Annex XIV to that Regulation and has concluded that it does not meet the conditions in Article 58(2). In particular, in the light of that judgement, Regulation (EC) No 726/2004, and Directives 2001/82/EC and 2001/83/EC do not constitute existing specific Union legislation imposing minimum requirements relating to the protection of human health or the environment for the use of DEHP, BBP and DBP in immediate packaging of medicinal products within the meaning of Article 58(2) of Regulation No 1907/2006 since they do not contain provisions specific to those substances imposing such requirements. Furthermore, Regulation (EC) No 726/2004 and Directives 2001/82/EC and 2001/83/EC lay down requirements related to the protection of human health only, while, as regards DEHP, intrinsic properties relating to hazards for the environment have been included in the entry for that substance in Annex XIV to Regulation (EC) No 1907/2006. Those exemptions are therefore not justified and should be deleted.
Recital 5, Regulation (EU) 2021/2045
In forcesince 23 Nov 2021
Judgment of the Court (Sixth Chamber) of 13 July 2017. Verein zur Wahrung von Einsatz und Nutzung von Chromtrioxid und anderen Chrom-VI-verbDecision
13 Jul 2017 · 62015CJ0651
Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 Decembe…58Law
Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 20…Law
Commission Regulation (EU) No 143/2011 of 17 February 2011 amending Annex XIV to Regulat…Law
- celex=32001L0082
- ecli=ECLI:UE:C:2017:543
- num:eu=2001/82